Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection

Do Young Kim, Hong Jeoung Kim, Chun Kyon Lee, Jeong Hun Suh, Dong Hwan Kim, Yong Suk Cho, Sun Young Won, Byung Kyu Park, In Suh Park

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background and Aims: Adefovir dipivoxil (ADV) is a nucleotide analogue that is known to be effective for lamivudine-resistant hepatitis B virus (HBV) mutants as well as wild-type HBV. The aim of this study is to assess the efficacy of ADV against lamivudine-resistant genotype C HBV mutants. Methods: Thirty-five patients with breakthrough hepatitis due to lamivudine-resistant HBV received ADV 10mg daily with discontinuation of lamivudine. Quantitative HBV DNA, HBeAg, liver function test including alanine aminotransferase (ALT) was checked every 4-12 weeks to evaluate the efficacy of ADV. Results: ADV was administered for a median of 48 weeks (range: 24-120 weeks). The rate of serum HBV DNA loss was 68.6%, 80.0%, 84.0%, and 88.2% at weeks 12, 24, 36, and 48, respectively. The rate of serum HBeAg seroconversion was 8.3% and 14.3% at weeks 24 and 48, respectively. The rate of serum ALT normalization at week 48 was 70.6%. Within 32 weeks after stopping ADV therapy, serum HBV DNA levels increased to a median of 378.9pg/ml in 88.9% of patients, who were treated for a median of 40 weeks. Moreover, in some patients, the ALT level increased to more than five times the upper limit of normal. Conclusions: Administration of ADV is an effective option for the treatment of patients with lamivudine-resistant genotype C HBV infection.

Original languageEnglish
Pages (from-to)47-53
Number of pages7
JournalLiver International
Volume27
Issue number1
DOIs
Publication statusPublished - 2007 Feb 1

Fingerprint

Lamivudine
Hepatitis B virus
Genotype
Infection
Alanine Transaminase
Hepatitis B e Antigens
Therapeutics
Serum
DNA
adefovir dipivoxil
Liver Function Tests
Virus Diseases
Hepatitis
Nucleotides

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

Kim, Do Young ; Kim, Hong Jeoung ; Lee, Chun Kyon ; Suh, Jeong Hun ; Kim, Dong Hwan ; Cho, Yong Suk ; Won, Sun Young ; Park, Byung Kyu ; Park, In Suh. / Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection. In: Liver International. 2007 ; Vol. 27, No. 1. pp. 47-53.
@article{eb1de5655511434db37f0206c39bd5d6,
title = "Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection",
abstract = "Background and Aims: Adefovir dipivoxil (ADV) is a nucleotide analogue that is known to be effective for lamivudine-resistant hepatitis B virus (HBV) mutants as well as wild-type HBV. The aim of this study is to assess the efficacy of ADV against lamivudine-resistant genotype C HBV mutants. Methods: Thirty-five patients with breakthrough hepatitis due to lamivudine-resistant HBV received ADV 10mg daily with discontinuation of lamivudine. Quantitative HBV DNA, HBeAg, liver function test including alanine aminotransferase (ALT) was checked every 4-12 weeks to evaluate the efficacy of ADV. Results: ADV was administered for a median of 48 weeks (range: 24-120 weeks). The rate of serum HBV DNA loss was 68.6{\%}, 80.0{\%}, 84.0{\%}, and 88.2{\%} at weeks 12, 24, 36, and 48, respectively. The rate of serum HBeAg seroconversion was 8.3{\%} and 14.3{\%} at weeks 24 and 48, respectively. The rate of serum ALT normalization at week 48 was 70.6{\%}. Within 32 weeks after stopping ADV therapy, serum HBV DNA levels increased to a median of 378.9pg/ml in 88.9{\%} of patients, who were treated for a median of 40 weeks. Moreover, in some patients, the ALT level increased to more than five times the upper limit of normal. Conclusions: Administration of ADV is an effective option for the treatment of patients with lamivudine-resistant genotype C HBV infection.",
author = "Kim, {Do Young} and Kim, {Hong Jeoung} and Lee, {Chun Kyon} and Suh, {Jeong Hun} and Kim, {Dong Hwan} and Cho, {Yong Suk} and Won, {Sun Young} and Park, {Byung Kyu} and Park, {In Suh}",
year = "2007",
month = "2",
day = "1",
doi = "10.1111/j.1478-3231.2006.01407.x",
language = "English",
volume = "27",
pages = "47--53",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "1",

}

Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection. / Kim, Do Young; Kim, Hong Jeoung; Lee, Chun Kyon; Suh, Jeong Hun; Kim, Dong Hwan; Cho, Yong Suk; Won, Sun Young; Park, Byung Kyu; Park, In Suh.

In: Liver International, Vol. 27, No. 1, 01.02.2007, p. 47-53.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection

AU - Kim, Do Young

AU - Kim, Hong Jeoung

AU - Lee, Chun Kyon

AU - Suh, Jeong Hun

AU - Kim, Dong Hwan

AU - Cho, Yong Suk

AU - Won, Sun Young

AU - Park, Byung Kyu

AU - Park, In Suh

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Background and Aims: Adefovir dipivoxil (ADV) is a nucleotide analogue that is known to be effective for lamivudine-resistant hepatitis B virus (HBV) mutants as well as wild-type HBV. The aim of this study is to assess the efficacy of ADV against lamivudine-resistant genotype C HBV mutants. Methods: Thirty-five patients with breakthrough hepatitis due to lamivudine-resistant HBV received ADV 10mg daily with discontinuation of lamivudine. Quantitative HBV DNA, HBeAg, liver function test including alanine aminotransferase (ALT) was checked every 4-12 weeks to evaluate the efficacy of ADV. Results: ADV was administered for a median of 48 weeks (range: 24-120 weeks). The rate of serum HBV DNA loss was 68.6%, 80.0%, 84.0%, and 88.2% at weeks 12, 24, 36, and 48, respectively. The rate of serum HBeAg seroconversion was 8.3% and 14.3% at weeks 24 and 48, respectively. The rate of serum ALT normalization at week 48 was 70.6%. Within 32 weeks after stopping ADV therapy, serum HBV DNA levels increased to a median of 378.9pg/ml in 88.9% of patients, who were treated for a median of 40 weeks. Moreover, in some patients, the ALT level increased to more than five times the upper limit of normal. Conclusions: Administration of ADV is an effective option for the treatment of patients with lamivudine-resistant genotype C HBV infection.

AB - Background and Aims: Adefovir dipivoxil (ADV) is a nucleotide analogue that is known to be effective for lamivudine-resistant hepatitis B virus (HBV) mutants as well as wild-type HBV. The aim of this study is to assess the efficacy of ADV against lamivudine-resistant genotype C HBV mutants. Methods: Thirty-five patients with breakthrough hepatitis due to lamivudine-resistant HBV received ADV 10mg daily with discontinuation of lamivudine. Quantitative HBV DNA, HBeAg, liver function test including alanine aminotransferase (ALT) was checked every 4-12 weeks to evaluate the efficacy of ADV. Results: ADV was administered for a median of 48 weeks (range: 24-120 weeks). The rate of serum HBV DNA loss was 68.6%, 80.0%, 84.0%, and 88.2% at weeks 12, 24, 36, and 48, respectively. The rate of serum HBeAg seroconversion was 8.3% and 14.3% at weeks 24 and 48, respectively. The rate of serum ALT normalization at week 48 was 70.6%. Within 32 weeks after stopping ADV therapy, serum HBV DNA levels increased to a median of 378.9pg/ml in 88.9% of patients, who were treated for a median of 40 weeks. Moreover, in some patients, the ALT level increased to more than five times the upper limit of normal. Conclusions: Administration of ADV is an effective option for the treatment of patients with lamivudine-resistant genotype C HBV infection.

UR - http://www.scopus.com/inward/record.url?scp=33846422423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846422423&partnerID=8YFLogxK

U2 - 10.1111/j.1478-3231.2006.01407.x

DO - 10.1111/j.1478-3231.2006.01407.x

M3 - Article

C2 - 17241380

AN - SCOPUS:33846422423

VL - 27

SP - 47

EP - 53

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 1

ER -